Emerging immunotherapies for malignant glioma: From immunogenomics to cell therapy

Gavin P. Dunn*, Timothy F. Cloughesy, Marcela V. Maus, Robert M. Prins, David A. Reardon, Adam M. Sonabend

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


As immunotherapy assumes a central role in the management of many cancers, ongoing work is directed at understanding whether immune-based treatments will be successful in patients with glioblastoma (GBM). Despite several large studies conducted in the last several years, there remain no FDA-approved immunotherapies in this patient population. Nevertheless, there are a range of exciting new approaches being applied to GBM, all of which may not only allow us to develop new treatments but also help us understand fundamental features of the immune response in the central nervous system. In this review, we summarize new developments in the application of immune checkpoint blockade, from biomarker-driven patient selection to the timing of treatment. Moreover, we summarize novel work in personalized immune-oncology by reviewing work in cancer immunogenomics-driven neoantigen vaccine studies. Finally, we discuss cell therapy efforts by reviewing the current state of chimeric antigen receptor T-cell therapy.

Original languageEnglish (US)
Pages (from-to)1425-1438
Number of pages14
Issue number10
StatePublished - Oct 1 2020


  • CNS immunosurveillance
  • Cancer immunogenomics
  • Glioblastoma
  • Neoantigen
  • Personalized vaccine

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'Emerging immunotherapies for malignant glioma: From immunogenomics to cell therapy'. Together they form a unique fingerprint.

Cite this